Evidence map›Paper›PMID 40491485›Full record

ArticleiScience2025

Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site.

Leah Liu Wang, Patrick Keiser, Derek Yang, Javier Seravalli, J J Patten, Brett Eaton, Dirk Anderson, Yi Liu, Michael R Holbrook, Amos B Smith and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leah Liu WangSchool of Veterinary Medicine and Biomedical Sciences and Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
Patrick KeiserNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 0211, USA.
Derek YangDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA.
Javier SeravalliDepartment of Biochemistry and Nebraska Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
J J PattenNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 0211, USA.
Brett EatonIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, Frederick, MD 21702, USA.
Dirk AndersonDepartment of Biochemistry and Nebraska Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
Yi LiuHolland Computing Center, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
Michael R HolbrookIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, Frederick, MD 21702, USA.
Amos B SmithDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA.
Robert A DaveyNational Emerging Infectious Diseases Laboratories, Boston University, Boston, MA 0211, USA.
Shi-Hua XiangSchool of Veterinary Medicine and Biomedical Sciences and Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human CD4 (cluster of differentiation 4) is well known as the primary receptor for human immunodeficiency virus (HIV) entry into the cells. The virus binds to CD4 molecules to induce a conformational change in the viral glycoprotein (GP) gp120, which exposes the co-receptor binding site for coreceptors CCR5 or CXCR4. The co-receptor binding then leads to membrane fusion for viral entry. Since the CD4 molecule has a high affinity for gp120, soluble CD4 (sCD4) and CD4-mimetic small molecules (CD4mcs) have been extensively studied as potential inhibitors for HIV infection. Surprisingly, we have found that human sCD4 and some CD4mcs are able to inhibit Ebola virus (EBOV) infection. Evidence is provided that the compounds block viral entry by targeting the GP binding site for the endosomal receptor Niemann-Pick C1 (NPC1). This finding reveals virus-receptor binding similarities between two remote viruses (HIV and EBOV) and suggests new possibilities for EBOV entry inhibitors.

Indexed as

Biological sciencesImmunologyMicrobiologyNatural sciencesVirology

Identifiers

PMID40491485
PMCPMC12148371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.